MNKYPOX Mpox (Monkeypox) clade 1b International Emergency Thread

helen

Panic Sex Lady
(fair use applies)


Concerns rise as new virulent Mpox variants could have possibly originated from U.S. NIAID labs
Nikhil Prasad Fact checked by:Thailand Medical News Team
Sep 01, 2024 3 hours, 55 minutes ago

The origins of the new and more virulent strains of the Mpox virus, which have been increasingly spreading across different regions, have become a focal point of controversy. Recent findings and political investigations have pointed fingers at the National Institute of Allergy and Infectious Diseases (NIAID), accusing them of creating these transmissible variants in their labs. The implications of these allegations are severe, raising questions about the safety and ethics of such research, the potential for future outbreaks, and the responsibility of governmental agencies in controlling and managing such risky experiments.


Allegations Against the NIAID: A Lab-Made Virus?
The House Republicans recently criticized the National Institutes of Health (NIH), under which NIAID operates, for its evasive responses to inquiries about risky research involving the Mpox virus. The controversy centers on a study that allegedly involved engineering the Mpox virus to become more transmissible and virulent, sparking fears that these lab-made variants could have accidentally or intentionally escaped the confines of the laboratory.


https://www.science.org/content/art...vasive-answers-on-risky-monkeypox-virus-study

E&C Leaders Request Top NIH Researcher Sit for Videotaped Interview After Admin Stalls on Providing Lethal Mpox Experiment Documents

https://www.science.org/content/article/will-monkeypox-virus-become-more-dangerous

The accusations, if proven true, would represent a serious breach of biosecurity protocols and raise ethical concerns about the role of government-funded research in potentially creating public health threats. House Republicans have been particularly vocal in their criticism, demanding transparency and accountability from the NIH and NIAID. They argue that the public has a right to know about the nature of the research being conducted with taxpayer dollars, especially when it involves dangerous pathogens like the Mpox virus.


The NIAID's Response: A Denial of Wrongdoing
In response to these allegations, the NIAID has firmly denied any involvement in creating or releasing virulent strains of the Mpox virus. Officials from the agency have stated that their research is conducted under strict s afety protocols and is designed to better understand the virus and develop potential treatments or vaccines, rather than to enhance its virulence or transmissibility.

However, the NIAID's assurances have done little to quell the concerns of critics, who argue that the agency's lack of transparency and its refusal to provide detailed information about the research have only fueled suspicions. Some experts in the field of biosecurity have also expressed concern that even well-intentioned research can lead to unintended consequences, particularly when it involves manipulating the genetic makeup of dangerous pathogens.


The Growing Threat of More Dangerous Mpox Variants
The concerns surrounding the NIAID's research come at a time when the Mpox virus is already undergoing significant mutations that are making it more dangerous. According to recent studies, new variants of the Mpox virus have emerged that are more transmissible and have higher rates of severe disease compared to earlier strains. These changes in the virus's behavior have raised alarms among public health officials and scientists, who fear that the situation could worsen if these variants continue to spread.

Thailand Medical News warns that not just are the new Clade 1b and Clade 2b variants becoming more transmissible but they seem to be rapidly mutating and spawning newer lineages at unprecedented rates.

GISAID - Mpox Variants Dashboard

The possibility that these more virulent strains could have originated in a laboratory setting only adds to the urgency of addressing this issue. If true, it would mean that the very institutions tasked with protecting public health could have inadvertently contributed to the evolution of a more dangerous pathogen, thereby increasing the risk of future outbreaks.


Political Fallout and Calls for Greater Oversight
The controversy over the NIAID's alleged involvement in creating new Mpox variants has sparked a broader debate about the oversight of government-funded research involving dangerous pathogens. Lawmakers on both sides of the aisle have called for greater transparency and accountability, with some even suggesting that the NIH and NIAID should face stricter regulations to prevent similar incidents from occurring in the future.

In June 2024, key figures from the House Energy and Commerce Committee requested a videotaped interview with a top NIH researcher involved in the Mpox study. The committee's leaders have expressed frustration with what they perceive as the NIH's attempts to stall the investigation by withholding critical documents related to the study. This has only deepened the distrust between the NIH and lawmakers, who are increasingly questioning whether the agency can be trusted to self-regulate its research activities.


Implications for Future Research and Public Health
The allegations against the NIAID, if substantiated, could have far-reaching implications for the future of biomedical research. There is a growing concern that public mistrust in government agencies could lead to increased skepticism about scientific research in general, particularly studies involving infectious diseases. This could have a chilling effect on research that is crucial for understanding and combating emerging pathogens, as scientists may become more hesitant to pursue projects that could be perceived as risky or controversial.

At the same time, the controversy highlights the need for a more robust framework for regulating research involving dangerous pathogens. Some experts have suggested that an independent oversight body should be established to monitor such research and ensure that it is conducted safely and ethically. This could help to restore public confidence in the scientific community and prevent future incidents that could jeopardize public health.


Conclusion: The Need for Vigilance and Transparency
The ongoing investigation into the NIAID's research activities serves as a stark reminder of the potential risks associated with biomedical research involving dangerous pathogens. While the pursuit of knowledge is essential for advancing public health, it must be balanced with a commitment to safety, transparency, and accountability. As the world continues to grapple with the threat of emerging infectious diseases, it is more important than ever to ensure that research is conducted in a way that minimizes the risk of unintended consequences.

The study findings and the investigation's outcome will likely shape the future of research involving pathogens like the Mpox virus. For now, the public and policymakers alike will be watching closely to see how the situation unfolds.
This is very bad news.
 

helen

Panic Sex Lady
This outbreak is near the border crossing in Kenya where the first mpox clade 1b case was found in a trucker.

Edited to add: The sick adults have surely had measles as children. The measles theory may be buying time.



Two dead, 10 sick with 'Mpox' symptoms

Two dead, 10 sick with 'Mpox' symptoms -The Standard Health
www.standardmedia.co.ke

A 10-year-old child died yesterday, in a remote village between Taita and Kwale, bringing the total number of deaths from a mysterious disease to two.

The father of the 10-year Emmanuel Mbui Beja said the boy had symptoms similar to those of Monkeypox like rashes, fever, and headache. He said that pupils in a local school have the same symptoms.

The Taita Taveta County government yesterday dispatched a team of health officials to the affected Zungulukani village, 70 kilometres away from Voi town amid panic from villagers.

The Disease Surveillance Coordinator in Voi Sub County Mr Johnston Kishagha said the patients have fever, rushes, headaches, red eyes, and vomit. He said blood samples have been taken to the lab for testing.

"We have collected samples from two children and an adult with the symptoms for lab tests," said Kishagha, who ruled out an outbreak of Monkeypox, saying he suspected that they were cases of measles.

He told the villages to avoid consuming bushmeat and untested meat to avoid infection.

However, Mr Beja said at least 10 villagers, including his brother and sister, are suffering from the strange disease, which has not been diagnosed. The disease has also disrupted learning in a local primary school, he said.

“We have dispatched a team of health officials to the ground and once we get a comprehensive report, we will share it with the press,” “said Harrison Kamwana, the senior communications officer.

Mr Beja said in the last week, members of his family had been suffering from the rare disease and he assumed that it was just a normal illness. The first case of death was from a different family.

Beja said the situation worsened after his brother and sister also fell sick from the disease and were rushed to Mackinnon Road Township Health Centre.

“We do not know exactly what is ailing the village because we have been assuming that it is an outbreak of measles, said Beja, adding that the local hospital has no drugs and equipment to detect diseases.

“The victims have been suffering from severe headaches, rashes, high temperature, and pale eyes,” he said, adding that his sister and brother were in critical condition.

“And due to the lack of drugs, we have resorted to traditional treatment because the entire village is sick and suffering from the disease. The sick are yet to be diagnosed by the government,” noted Beja.

Last week, the Taita Taveta County government announced that it had partnered with the national government to stop the spread of Monkeypox.

“We have partnered with the national government and other relevant stakeholders to provide the necessary information about the disease and take preventive measures.

We have also enhanced surveillance as crucial steps to managing the rapid spread of the disease,” said the health officer in Taveta Sub County.

The county is still grappling with a persistent shortage of drugs in public hospitals, with children, elderly, and other vulnerable groups bearing the brunt.

The first case of Monkeypox was detected at the Taveta border post early this month after a foreigner was put in quarantine at the Taveta One Shop border stop Quarantine Centre.

At least four people have tested positive for the Monkeypox in Kenya.

Health authorities disclosed that the Ugandan national was traveling from Mombasa to Rwanda through Tanzania when the case was detected at the Taveta border point.

Health officials stated that the individual from Uganda appeared tired and had abnormal body temperatures. He was weak and feeling fever and joint pains before he tested positive for the disease.

The East African Community (EAC) Secretariat has also called on EAC Partner States to educate their citizens on how to protect themselves and prevent the spread of Mpox (Monkeypox).

This follows reports from the World Health Organization (WHO) that Burundi and the Democratic Republic of Congo (DRC) are experiencing an outbreak of the viral Mpox disease.

The virus spreads from animals to humans and between people through close contact, contaminated objects, and respiratory droplets.

Symptoms include a skin rash or lesions, fever, intense headache, muscle aches, back pain, general body weakness, and swollen lymph nodes, typically lasting two to four weeks. While most cases are moderate, severe cases of ox (monkeypox) is an infectious disease caused by the monkeypox virus. It can cause a painful rash, enlarged lymph nodes, and fever. Most people fully recover, but some get very sick.


 

Tristan

TB Fanatic
(fair use applies)


Concerns rise as new virulent Mpox variants could have possibly originated from U.S. NIAID labs
Nikhil Prasad Fact checked by:Thailand Medical News Team
Sep 01, 2024 3 hours, 55 minutes ago

The origins of the new and more virulent strains of the Mpox virus, which have been increasingly spreading across different regions, have become a focal point of controversy. Recent findings and political investigations have pointed fingers at the National Institute of Allergy and Infectious Diseases (NIAID), accusing them of creating these transmissible variants in their labs. The implications of these allegations are severe, raising questions about the safety and ethics of such research, the potential for future outbreaks, and the responsibility of governmental agencies in controlling and managing such risky experiments.


Allegations Against the NIAID: A Lab-Made Virus?
The House Republicans recently criticized the National Institutes of Health (NIH), under which NIAID operates, for its evasive responses to inquiries about risky research involving the Mpox virus. The controversy centers on a study that allegedly involved engineering the Mpox virus to become more transmissible and virulent, sparking fears that these lab-made variants could have accidentally or intentionally escaped the confines of the laboratory.


https://www.science.org/content/art...vasive-answers-on-risky-monkeypox-virus-study

E&C Leaders Request Top NIH Researcher Sit for Videotaped Interview After Admin Stalls on Providing Lethal Mpox Experiment Documents

https://www.science.org/content/article/will-monkeypox-virus-become-more-dangerous

The accusations, if proven true, would represent a serious breach of biosecurity protocols and raise ethical concerns about the role of government-funded research in potentially creating public health threats. House Republicans have been particularly vocal in their criticism, demanding transparency and accountability from the NIH and NIAID. They argue that the public has a right to know about the nature of the research being conducted with taxpayer dollars, especially when it involves dangerous pathogens like the Mpox virus.


The NIAID's Response: A Denial of Wrongdoing
In response to these allegations, the NIAID has firmly denied any involvement in creating or releasing virulent strains of the Mpox virus. Officials from the agency have stated that their research is conducted under strict s afety protocols and is designed to better understand the virus and develop potential treatments or vaccines, rather than to enhance its virulence or transmissibility.

However, the NIAID's assurances have done little to quell the concerns of critics, who argue that the agency's lack of transparency and its refusal to provide detailed information about the research have only fueled suspicions. Some experts in the field of biosecurity have also expressed concern that even well-intentioned research can lead to unintended consequences, particularly when it involves manipulating the genetic makeup of dangerous pathogens.


The Growing Threat of More Dangerous Mpox Variants
The concerns surrounding the NIAID's research come at a time when the Mpox virus is already undergoing significant mutations that are making it more dangerous. According to recent studies, new variants of the Mpox virus have emerged that are more transmissible and have higher rates of severe disease compared to earlier strains. These changes in the virus's behavior have raised alarms among public health officials and scientists, who fear that the situation could worsen if these variants continue to spread.

Thailand Medical News warns that not just are the new Clade 1b and Clade 2b variants becoming more transmissible but they seem to be rapidly mutating and spawning newer lineages at unprecedented rates.

GISAID - Mpox Variants Dashboard

The possibility that these more virulent strains could have originated in a laboratory setting only adds to the urgency of addressing this issue. If true, it would mean that the very institutions tasked with protecting public health could have inadvertently contributed to the evolution of a more dangerous pathogen, thereby increasing the risk of future outbreaks.


Political Fallout and Calls for Greater Oversight
The controversy over the NIAID's alleged involvement in creating new Mpox variants has sparked a broader debate about the oversight of government-funded research involving dangerous pathogens. Lawmakers on both sides of the aisle have called for greater transparency and accountability, with some even suggesting that the NIH and NIAID should face stricter regulations to prevent similar incidents from occurring in the future.

In June 2024, key figures from the House Energy and Commerce Committee requested a videotaped interview with a top NIH researcher involved in the Mpox study. The committee's leaders have expressed frustration with what they perceive as the NIH's attempts to stall the investigation by withholding critical documents related to the study. This has only deepened the distrust between the NIH and lawmakers, who are increasingly questioning whether the agency can be trusted to self-regulate its research activities.


Implications for Future Research and Public Health
The allegations against the NIAID, if substantiated, could have far-reaching implications for the future of biomedical research. There is a growing concern that public mistrust in government agencies could lead to increased skepticism about scientific research in general, particularly studies involving infectious diseases. This could have a chilling effect on research that is crucial for understanding and combating emerging pathogens, as scientists may become more hesitant to pursue projects that could be perceived as risky or controversial.

At the same time, the controversy highlights the need for a more robust framework for regulating research involving dangerous pathogens. Some experts have suggested that an independent oversight body should be established to monitor such research and ensure that it is conducted safely and ethically. This could help to restore public confidence in the scientific community and prevent future incidents that could jeopardize public health.


Conclusion: The Need for Vigilance and Transparency
The ongoing investigation into the NIAID's research activities serves as a stark reminder of the potential risks associated with biomedical research involving dangerous pathogens. While the pursuit of knowledge is essential for advancing public health, it must be balanced with a commitment to safety, transparency, and accountability. As the world continues to grapple with the threat of emerging infectious diseases, it is more important than ever to ensure that research is conducted in a way that minimizes the risk of unintended consequences.

The study findings and the investigation's outcome will likely shape the future of research involving pathogens like the Mpox virus. For now, the public and policymakers alike will be watching closely to see how the situation unfolds.


Disappointing.

Not surprising.
 

Tristan

TB Fanatic
(fair use applies)


Scientists warned in 2009 that Vaccinia virus in current Mpox vaccines impairs critical immune functions
Nikhil Prasad Fact checked by:Thailand Medical News Team
Aug 29, 2024


A Glimpse into the Past: The Warning That Went Unheeded
In 2009, a group of scientists from the Brody School of Medicine at East Carolina University-USA, led by Dr. Rachel L. Roper, raised alarm bells about the potential dangers of the Vaccinia virus (VACV) used in Mpox (previously known as monkeypox) and smallpox vaccines. Their groundbreaking research, published in a peer-reviewed journal, indicated that the virus might impair critical functions of the immune system, specifically targeting antigen-presenting cells (APCs). This Medical News report delves into their findings and the implications that continue to resonate today.

It should be noted that while these vaccines were ‘seemingly ok’ in the past, we are currently in a different situation as we have huge populations of people already having immune dysfunction issues caused by COVID-19, SARS-CoV-2 reinfections and even by the COVID-19 mRNA vaccines. We also have growing populations of people with HIV and cancer and as such immunocompromised to a certain degree and also many who had been exposed to measles recently not forgetting that we are dealing with newer strains of Mpox now.


Understanding the Role of Antigen-Presenting Cells
Antigen-presenting cells are a crucial component of the immune system, responsible for detecting and presenting foreign antigens to T cells. This interaction is vital for initiating an effective immune response against pathogens. The study conducted by Dr. Roper and her team highlighted how VACV, the virus used in smallpox and Mpox vaccines, disrupts this critical process, potentially weakening the body's ability to fight off infections.

According to the research, VACV significantly decreases the presentation of major histocompatibility complex (MHC) class II molecules, which are essential for the activation of T cells. The virus also impairs the production of important cytokines and chemokines, further inhibiting the immune response. This article provides a detailed analysis of these findings and their potential implications for vaccine safety.


Key Findings of the Study
The study focused on how VACV interacts with different types of antigen-presenting cells, including macrophages, dendritic cells, and B cells. The researchers found that VACV infection led to a significant reduction in MHC class II antigen presentation across all these cell types. This reduction was linked to a decrease in the amount of antigenic peptide loaded into MHC class II molecules, which is essential for T cell activation.

The researchers discovered that VACV specifically targets macrophages and dendritic cells, inducing apoptosis (programmed cell death) in these cells. This apoptosis contributes to the impaired antigen presentation, further weakening the immune response. Interestingly, B cells were affected differently; while VACV reduced their ability to present antigens, it did not induce apoptosis in these cells, suggest ing a distinct mechanism of immune evasion by the virus.


Implications for Vaccine Safety
The findings of this study raise important questions about the safety and efficacy of vaccines that use VACV as a platform. While VACV-based vaccines have been highly effective in eradicating smallpox and controlling Mpox outbreaks, the potential for immune suppression poses a significant concern, especially for individuals with compromised immune systems.

The researchers noted that VACV's ability to impair antigen presentation could lead to reduced vaccine efficacy, particularly in individuals with pre-existing conditions or weakened immune systems. This impairment might also increase the risk of adverse reactions, such as disseminated poxvirus infections, which have been reported in some vaccine recipients.


The Broader Context: Immune Evasion by Poxviruses
Poxviruses, including VACV, are known for their ability to evade the host immune system. The study by Roper and her team adds to the growing body of evidence that these viruses employ multiple strategies to subvert immune defenses. In addition to impairing antigen presentation, VACV has been shown to block the production of nitric oxide (NO), a key molecule involved in antiviral defense. The virus also reduces the expression of MHC class II molecules on the surface of APCs, further hindering the immune response.

The study findings highlight the importance of understanding these immune evasion mechanisms, as they have significant implications for vaccine design and the development of antiviral therapies. The study findings underscore the need for continued research into the interactions between VACV and the immune system, particularly in the context of vaccine safety.


Expanding on the Study's Findings
The study conducted by the Brody School of Medicine at East Carolina University was comprehensive, employing various experimental models to investigate the effects of VACV on antigen presentation. The researchers used rat peritoneal macrophages, dendritic cells, and a mouse B-cell line to assess how VACV infection impacts the immune response.

Their experiments revealed that VACV infection significantly reduced the production of interleukin-2 (IL-2), a critical cytokine for T cell activation, in response to antigen presentation. This reduction was observed across different types of APCs, indicating that VACV has a broad impact on the immune system. The researchers also found that increasing the concentration of antigens could partially restore antigen presentation in infected cells, suggesting that VACV disrupts antigen processing rather than directly killing APCs.

The study also explored how VACV affects cytokine production in response to antigen presentation. The researchers found that VACV infection led to a significant decrease in the production of multiple cytokines, including tumor necrosis factor-alpha (TNF-a), interleukin-1 (IL-1), and macrophage inflammatory protein-1 alpha (MIP-1a). These cytokines play essential roles in coordinating the immune response and recruiting immune cells to the site of infection.


Conclusion: The Need for Caution and Further Research
The study's findings highlight the complex interplay between VACV and the immune system, raising important questions about the long-term safety and efficacy of VACV-based vaccines. While these vaccines have been instrumental in controlling poxvirus outbreaks, the potential for immune suppression cannot be overlooked.

As the world continues to grapple with emerging infectious diseases, the need for safe and effective vaccines has never been greater. This article underscores the importance of continued research into the immune evasion mechanisms employed by VACV and other poxviruses. Such research is crucial for developing next-generation vaccines that are both safe and effective, particularly for vulnerable populations.

The study findings were published in the peer-reviewed journal Immunology.


Well, that fits the trend-curve.
 

phloydius

Veteran Member
They’re frantically trying to downplay this before true panic hits.


Yeah. A couple of important notes from the article:

  • Although they say "at least 10 villagers" are sick, they also say the "entire village is sick and suffering from the disease"
  • These won't be included in the confirmed cases, most likely because "the local hospital has no drugs and equipment to detect diseases"
  • They "ruled out an outbreak of Monkeypox" but told the villagers "to avoid consuming bushmeat and untested meat to avoid infection" which is a precaution for Monkeypox not Measles
  • "Blood samples" were taken to test, but Monkeypox is very rare to detect in the blood. To test for Monkeypox, puss is ideal, or a scraping of the rash if no puss yet.

TLRD; So if they have Monkeypox, we probably won't know for sure, because they are not really testing for it.
 

psychgirl

TB Fanatic
Yeah. A couple of important notes from the article:

  • Although they say "at least 10 villagers" are sick, they also say the "entire village is sick and suffering from the disease"
  • These won't be included in the confirmed cases, most likely because "the local hospital has no drugs and equipment to detect diseases"
  • They "ruled out an outbreak of Monkeypox" but told the villagers "to avoid consuming bushmeat and untested meat to avoid infection" which is a precaution for Monkeypox not Measles
  • "Blood samples" were taken to test, but Monkeypox is very rare to detect in the blood. To test for Monkeypox, puss is ideal, or a scraping of the rash if no puss yet.

TLRD; So if they have Monkeypox, we probably won't know for sure, because they are not really testing for it.
If it wasn’t pox, no warning would be given for bush meat

They’re frantic CYA mode
 

helen

Panic Sex Lady
Most YouTube news videos from affected countries show their military at the checkpoints.

Pakistan's fifth case came from Jeddah.

The African clinics are overwhelmed. You see people crammed together on benches with yards of fabric on their bodies and little sanitation.

Maybe Africa couldn't get the vaccines early enough to prevent this because the pharma pushers know they don't really work.

Just rambling thoughts.

My expiration date (due to vax) is September 10. I've got two households with COVID positive tests and I've been all over the patients without getting sick. Is the vax working?
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Oregon doctors warn of potential cardiac issues linked to JYNNEOS Mpox vaccine

Nikhil Prasad Fact checked by:Thailand Medical News Team
Sep 01, 2024

Based on a past study finding, Oregon-based researchers have raised concerns regarding the potential cardiac risks associated with the JYNNEOS vaccine 9made by Danish company - Bavarian Nordic, which is currently being advocated and promoted for use to prevent monkeypox (Mpox). This warning comes after a comprehensive study was conducted by experts from the Department of Infectious Diseases, the Department of Analytics, and the Department of Pediatrics at Kaiser Permanente Northwest, Portland, Oregon-USA. The researchers aimed to assess the incidence of cardiac adverse events of special interest (AESI) following the administration of the JYNNEOS vaccine (A MVA-BN vaccine) during the ongoing public health emergency.

The JYNNEOS vaccine, approved by the U.S. Food and Drug Administration (FDA), is a key tool in combating smallpox and monkeypox outbreaks. However, safety data from the FDA has flagged potential cardiac issues post-vaccination.


This Medical News report delves into the findings of the study and explores the implications for public health, particularly for individuals with pre-existing heart conditions.

It should be noted that Thailand Medical News had covered certain other studies that also warned about the effectiveness of the current Mpox vaccines and its possible adverse effects.

https://www.thailandmedical.news/ne...ent-in-protecting-against-emerging-mpox-virus

https://www.thailandmedical.news/ne...-cause-generalized-pustular-psoriasis-in-some


Study Methodology and Patient Demographics

The study was a retrospective cohort analysis that included 2,126 patients aged 12 and above, all of whom received at least one dose of the JYNNEOS vaccine between July 14, 2022, and October 10, 2022. The researchers examined electronic health records (EHR) from the Kaiser Permanente Northwest database, looking for signs of cardiac events, including elevated troponin levels, myocarditis, pericarditis, and other related conditions within 21 days post-vaccination.

The patient cohort primarily consisted of 1,811 males (85.2%), 290 females (13.6%), and 25 non-binary individuals (1.2%). The ages of the participants ranged from 12 to 82 years. Importantly, 1,077 patients received two doses of the vaccine, while a smaller group of 16 individuals received three doses.


Key Findings: Incidence of Cardiac Adverse Events

The researchers identified 24 possible cases of cardiac AESI using diagnostic codes and troponin values from patient records. However, after detailed physician review, only 10 of these cases were confirmed as cardiac AESI, yielding an incidence rate of 3.1 per 1,000 doses administered (with a 95% confidence interval of 1.5 to 5.7). This suggests that while the occurrence of such events is relatively rare, it is significant enough to warrant caution, especially in patients with pre-existing cardiac conditions.

Interestingly, none of the confirmed cardiac events could be directly attributed to the JYNNEOS vaccine itself. The study revealed that most of these events had alternative explanations. For instance, several cases were associated with underlying health conditions, such as obesity, hypertension, or pre-existing arrhythmias. Additionally, seven out of the ten patients experienced symptoms that were mild enough to be managed on an outpatient basis, with no hospitalizations or severe outcomes reported.


Understanding the Cardiac Risks

The U.S. FDA's safety data on the JYNNEOS vaccine had previously indicated potential cardiac risks, particularly in individuals with underlying heart disease or multiple cardiac risk factors. The Advisory Committee on Immunization Practices (ACIP) has also highlighted the theoretical risk of myopericarditis - a condition involving inflammation of the heart muscle and surrounding pericardium - following vaccination.

Despite these concerns, the study's findings provide some reassurance. Although cardiac AESI were identified, the lack of a direct link to the vaccine suggests that the overall risk remains low. This is particularly relevant for healthcare providers who are advising patients with pre-existing cardiac conditions. The study offers timely data to support informed decision-making during the ongoing public health emergency.


Implications for Public Health and Future Research

The results of this study are crucial for public health messaging, particularly in the context of widespread vaccination efforts. While the JYNNEOS vaccine is an essential tool in controlling the spread of monkeypox, it is vital to continue monitoring its safety profile, especially as more data becomes available.

Future research should focus on examining the incidence of cardiac AESI by dose number and route of administration (subcutaneous vs. intradermal). Additionally, the potential impact of pre-existing conditions on the rate of adverse events should be explored further. Such studies will help refine the risk-benefit analysis for the JYNNEOS vaccine, particularly in vulnerable populations.


Conclusion: Navigating Vaccine Safety

In conclusion, the study conducted by researchers at Kaiser Permanente Northwest highlights the importance of ongoing vigilance in monitoring vaccine safety. While the incidence of cardiac events following the JYNNEOS vaccination was found to be low, healthcare providers should remain cautious, particularly when vaccinating individuals with known cardiac risk factors.

The findings emphasize the need for physician adjudication to accurately determine the true incidence of adverse events. As the monkeypox public health emergency continues, it is essential to balance the benefits of vaccination against the potential risks, ensuring that patients receive the best possible care.

The study findings were published in the peer-reviewed journal: Reactions Weekly. (Behind a paywall sadly!)


A free preprint version of it can be found here:

 

helen

Panic Sex Lady
The upcoming problem with monkeypox is that the United States Supreme Court decided in favor of forced vaccination for smallpox.

They maimed and killed a lot of the vaccinated with sepsis and vaccine aqcuired vaccinia infections.

I wasn't forced to vax with economic pressure alone. It was the only way I could accompany elders into medical facilities. Blackmailed by love and duty if you will.

Monkeypox is visible and the pain is intense. No quiet sedated patients on vents. Vax is more likely to be demanded than coerced.

Thousands of vectors voluntarily got mpox vax and did not die. That was the field test. The human trial. You've already seen it in a highly visible vector population.
 

helen

Panic Sex Lady
They're popping blisters. If you check the number of confirmed cases and compare them with deaths, you get a high kill rate (13%). Sepsis may or may not be counted.

You know some people over here will pop blisters. Dear God. Pictures at the link tell you why it's way too late now.






Inside mpox wards where hundreds lie on dirt floors amid drug shortages


Inside makeshift mpox isolation wards where hundreds of patients lie on dirt floors amid life-threatening drug shortages

www.thesun.co.uk
IN a crowded emergency mpox isolation ward in eastern Congo, dozens of sick patients lie on thin mattresses on the hard dirt floor.

Hospital staff already stretched thin, are struggling with severe drug shortages to treat the virus and a lack of space to look after the surge in patients.

Nsimire Nakaziba 34, pricks the rashes on her sister Sifa Mwakasisi, 32 to relieve painCredit: Reuters

Congolese health workers are desperately waiting for vaccines to arriveCredit: Reuters
Desperate and uncertain, helpless mothers have resorted to popping their babies' painful blisters and creating makeshift remedies from salt and lemon.

The Democratic Republic of Congo has become the epicenter of an mutant mpox outbreak, which the World Health Organisation (WHO) recently declared a global public health emergency.

The new strain, called clade 1b is thought to be more dangerous than it's predecessor clade 2 - which spread internationally in 2022.

There were 19,710 suspected cases of the new clade reported since the start of the year in Congo by August 31, according to the health ministry.



Of those, 5,041 were confirmed and 655 were fatal.



In response to the spread of the new bug, vaccines are expected to arrive into the country within days to combat the new mutant strain.

However, at the hospital complex in the town of Kavumu, where 900 unwell patients have been admitted over the past three months, health workers are in urgent need of additional support.

"We run out of medicine every day," head doctor Musole Mulamba Muva, told Reuters.

"There are many challenges we struggle to overcome with our local means," he said.

UK could see ‘explosion’ of mpox cases in just TWO WEEKS – as threat of ‘double outbreak’ grows.

Last week, 135 patients, both children and adults, were crowded into the mpox ward.

Inside, they are seen squeezed between three large plastic tents set up on damp earth without any floor covering.

Relatives of sick patients, who typically provide most of the meals at places like Kavumu Hospital, have been banned from visiting the mpox ward to prevent the risk of contamination.

"We do not have anything to eat," said Nzigire Lukangira, the 32-year-old mother of a hospitalised toddler.

"When we ask for something to lower our children's temperature, they do not give us anything," she told the news site, while pouring honey into her daughter's mouth.

Mpox causes flu-like symptoms and pus-filled lesions and, while usually mild, it can kill.

It is spread through close contact with infected animals or people.

Sick people are resorting to herbal remedies while the drug shortage continuesCredit: Reuters

Suspected mpox patients wait for consultation at the mpox treatment centre at the Kavumu hospitalCredit: Reuters

The disease has ravaged the Congo and has since been found in EuropeCredit: Reuters
Children, pregnant women and people with weakened immune systems are all at higher risk of complications.

Although there are no specific treatment for mpox, but there are ways to help people recover and manage symptom which include antiviral medicines and painkillers.

DESPERATE MEASURES​

Like other mothers in the Kavumu mpox ward, Nzigire had started making traditional remedies to ease her baby's pain.

They dipped their fingers in potassium bicarbonate or salty lemon juice and popped their children's blisters.

Adult patients did the same to themselves.


Most cases came from the town itself and surrounding villages. Two other makeshift mpox wards have been set up in the area.

The currently available vaccine is a repurposed version of the smallpox vaccine, as the viruses are closely related.

It can be administered either before exposure to the virus or after contact has occurred.

Dr Jonas Albarnaz, a research fellow specialising in pox viruses at The Pirbright Institute, said:

"This news of a case of clade 1 mpox in Sweden is concerning for two main reasons.

"First, this is the first clade 1 mpox virus case outside Africa. This indicates that the extent of the international spread of clade 1 outbreak in DRC might be larger than we knew yesterday.

"And second, clade 1 mpox virus is associated with a more severe disease and higher mortality rates than the clade 2 virus responsible for the international mpox outbreak in 2022.

"This is hard to predict whether we will see further cases of clade 1 mpox outside of Africa, but this case in Sweden is a warning call for public health authorities to be vigilant and implement robust surveillance and contact-tracing strategies to detect possible new cases early on.

"It’s also critical to determine what is the link between this clade 1 mpox virus detected in Sweden and the ongoing outbreak in DCR."

The jab was credited for helping put an end to the 2022 outbreak.

However, experts are uncertain whether the same vaccine will be effective against the new strain.

It hasn't been tested against the more potent version of the bug, which has spread across Africa and more recently, Sweden and Thailand.

While no cases have yet been confirmed in the UK, experts suspect the new variant is already in Britain.

Due to how long it takes for symptoms to emerge, they believe we could see cases within the next two weeks.

However, Europe is unlikely to see as many deaths as central Africa due to better access to quality healthcare, they said.
 

Kayak

Adrenaline Junkie
I specifically remember, for either polio or smallpox, that they discovered having patients outside, in the sunlight, upped survivor chances immensely. An internet search pulls up nothing, but it makes sense to me that since sunlight DOES kill the mpox virus, that laying outside in the sun and exposing the blisters (full of the virus) could help. Yes?

Just thinking out loud and considering how best to deal with it, if it does actually arrive.
 

Meemur

Voice on the Prairie
Those pictures also highlight why the fatality rate will almost certainly be less if/when it arrives here.
That's what I'm online scanning for right now: waste water checks. Covid has increased in parts of Iowa, per waste water checks. I'm wondering when they will start looking for mpox. I realize those numbers could be made up to fit whatever narrative they are pushing, but if honest, they at least give me another heads up.
 

Kayak

Adrenaline Junkie
That's what I'm online scanning for right now: waste water checks. Covid has increased in parts of Iowa, per waste water checks. I'm wondering when they will start looking for mpox. I realize those numbers could be made up to fit whatever narrative they are pushing, but if honest, they at least give me another heads up.
Only if they check for the clade. We know Clade 2 variants are here and have been for over a year. I've seen a few cities post their mpox sewage numbers, but they don't show the clade, so as far as I'm concerned, it's just fear mongering at this point.
 

helen

Panic Sex Lady
Those pictures also highlight why the fatality rate will almost certainly be less if/when it arrives here.
I think you're right about that.

The COVID mess kept people from getting timely care for serious conditions, and the OTC meds and PPE were stripped from stores.

So mpox related deaths are still possible, but not from mpox per se. I wonder how many mpox deaths are conflated with sepsis?
 

Broccoli

Veteran Member
The numbers of children infected are surging, just as schools are back in session in the DRC

I'd be keeping the kids home and dosing them up with Ivermectin 'till the plague passed.

The schools have some responsibility in closing to mitigate the spread instead of waiting for it to become a disaster and forcing the shot on the kids. The cure is worse than the disease I am sure. amen

Get the kid a shot with unknown side effects, take a week off to care for them or find care for them for a week while you work? I can tell you which the devil choses. amen
 

Signwatcher

Has No Life - Lives on TB
I specifically remember, for either polio or smallpox, that they discovered having patients outside, in the sunlight, upped survivor chances immensely. An internet search pulls up nothing, but it makes sense to me that since sunlight DOES kill the mpox virus, that laying outside in the sun and exposing the blisters (full of the virus) could help. Yes?

Just thinking out loud and considering how best to deal with it, if it does actually arrive.

High levels of vitamin D boost the immune system.
 
Top